CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 158 enrolled
Drug / intervention
LGX818 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02159066
NCT02159066Phase 2Completed
CompareCT.gov

The LOGIC 2 Trial A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma.

Pfizer·interventional·Posted Jun 9, 2014·Updated Mar 5, 2024

In Brief

A Phase 2 clinical trial evaluating LGX818, MEK162, and 4 other interventions for Melanoma. Completed, enrolled 158 participants across 32 sites in 9 countries.

Detailed Summary

The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesAustralia, Canada, Germany, Italy, Netherlands, Spain, Switzerland, United Kingdom, United States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 9, 2014
Enrollment StartJul 23, 2014
Primary CompletionJan 10, 2023
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 12.1 years ago

Interventions

LGX818drug

Combination of LGX818 and MEK162 (Part I)

MEK162drug

Combination of LGX818 and MEK162 (Part I)

LEE011drug

Combination of LGX818 + MEK162 + LEE011 (Part II)

BGJ398drug

Combination of LGX818 + MEK162 + BGJ398 (Part II)

BKM120drug

Combination of LGX818 + MEK162 + BKM120 (Part II)

INC280drug

Combination of LGX818 + MEK162 + INC280 (Part II)